|1.||Chimenti, Sergio: 7 articles (01/2015 - 01/2004)|
|2.||Tanghetti, Emil: 7 articles (03/2013 - 06/2004)|
|3.||Sefton, John: 5 articles (02/2005 - 11/2002)|
|4.||Leyden, James J: 5 articles (02/2005 - 02/2002)|
|5.||Sefton, J: 5 articles (12/2004 - 10/2000)|
|6.||Feldman, Steven R: 4 articles (06/2015 - 02/2003)|
|7.||Epstein, Ervin H: 4 articles (04/2014 - 07/2004)|
|8.||Shalita, Alan: 4 articles (05/2010 - 10/2004)|
|9.||Tan, Sheng-shun: 4 articles (02/2009 - 08/2005)|
|10.||Peris, Ketty: 4 articles (01/2006 - 01/2004)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
10/01/1998 - "All tazarotene combinations (including tazarotene plus placebo) were highly effective in rapidly reducing the severity of psoriasis. "
05/01/1998 - "Combination treatment with tazarotene plus a mid- or high-potency corticosteroid was more effective in the treatment of psoriasis than tazarotene alone. "
07/01/1997 - "Once-daily tazarotene was effective and safe as a topical monotherapy for plaque psoriasis, providing rapid reduction of signs and symptoms."
07/01/1998 - "Treatment with tazarotene offers an opportunity to reduce the cost of care for patients with mild-to-moderate psoriasis and enhance patient satisfaction by gaining more disease-free days."
10/01/1996 - "Tazarotene effectively treats mild-to-moderate plaque-type psoriasis, the benefits seem to be sustained after the cessation of therapy, and once-daily treatment is equally effective as more frequent application."
04/01/2002 - "Local adverse effects did not differ significantly among the 3 groups after week 4. Short-contact 0.1% tazarotene gel therapy is a safe and effective new method of acne treatment."
01/01/2013 - "Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. "
06/01/1999 - "Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study."
08/01/2010 - "Topical tazarotene cream (0.1%) is a effective and safe treatment option for acne vulgaris affecting face. "
10/01/2004 - "These results indicate that topical tazarotene 0.1% gel and cream are efficacious and well-tolerated treatment options for clearing acne vulgaris across a broad range of patients."
01/01/2006 - "Once-daily application of tazarotene cream was shown to be effective against PIH, achieving significantly greater reductions compared with vehicle in overall disease severity and in the intensity and area of hyperpigmentation within 18 weeks (P< or =.05). "
11/01/2002 - "Compared with the vehicle, at week 24 tazarotene resulted in a significantly greater incidence of patients achieving treatment success (>or=50% global improvement) and at least a 1-grade improvement in fine wrinkling, mottled hyperpigmentation, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, and the overall integrated assessment of photodamage (P<.01). "
12/01/2004 - "In this multicentre, double-blind, randomized, vehicle-controlled study, 50 patients with photodamaged facial skin (at least mild fine wrinkling and mottled hyperpigmentation, with at least one of these being moderate) were randomized to apply tazarotene 0.1% cream or vehicle cream to their face, once daily for 24 weeks. "
06/01/2004 - "All significant between-group differences in efficacy measures were in favor of tazarotene - for fine wrinkling at the study endpoint and, at earlier timepoints, for treatment success (> or =50% global improvement), and the overall integrated assessment of photodamage, mottled hyperpigmentation, and coarse wrinkling. "
02/01/2005 - "Tazarotene cream was significantly more effective than vehicle in reducing fine wrinkles, mottled hyperpigmentation, lentigines, irregular depigmentation, apparent pore size, elastosis, tactile roughness, and an overall integrated assessment of photodamage. "
10/01/1998 - "Tazarotene 0.1% gel in combination with a mid- or high-potency corticosteroid, when compared with tazarotene plus placebo cream, achieved significantly greater reductions in scaling, erythema, and overall lesional severity, and a decreased incidence of adverse events. "
11/01/2012 - "Erythema grades and local skin reactions did not differ systematically by study product or across patch sites, and no pattern of increased reactivity at tazarotene foam 0.1% sites was observed. "
12/01/1999 - "This study investigates the dose of UVB light required to induce minimal erythema and the dose of UVA light required to induce immediate pigment darkening, with and without pretreatment with tazarotene 0.1% gel. "
10/01/1998 - "A 2-week pretreatment with tazarotene 0.1% gel once daily, followed by tazarotene plus UVB therapy (tazarotene-UVB) 3 times per week for 10 weeks, was more effective than UVB therapy alone or in combination with vehicle gel in reducing plaque elevation, scaling, and erythema. "
10/01/1998 - "For example, the steroid may promote a rapid initial response together with minimization of erythema during the treatment period, and tazarotene may prolong the duration of the therapeutic effect and lower the probability of relapse. "
10/01/1999 - "Short-term topical application of tazarotene 0.05% gel is a very effective and well-tolerated treatment modality in different forms of congenital ichthyoses and may be an alternative to systemic retinoid therapy."
01/01/2006 - "[Topical tazarotene for severe congenital ichthyosis]."
10/01/1999 - "The clinical efficacy and tolerability of the topical receptor-selective retinoid tazarotene in the treatment of congenital ichthyoses was investigated. "
10/01/1999 - "Effect of topical tazarotene in the treatment of congenital ichthyoses."
05/01/2013 - "We describe a patient with recessive ichthyosis for whom daily application of topical tazarotene produced rapid and persistent improvement of bilateral lower eyelid ectropion without adverse effects. "
|4.||Tretinoin (Retinoic Acid)
|7.||Clobetasol (Clobetasol Propionate)
|10.||Retinoic Acid Receptors (Retinoic Acid Receptor)
|4.||Phototherapy (Light Therapy)